Currently Viewing:
North American Neuroendocrine Tumor Society Symposium 2018
Currently Reading
Dr Thorvardur Halfdanarson Discusses Lack of Risk Factors, Biomarkers in NETs
December 04, 2018
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 08, 2018
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 06, 2018
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 01, 2018
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23, 2018
Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs
October 19, 2018
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17, 2018
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
October 07, 2018
A Comprehensive Look at Updates, Developments in NETs
October 07, 2018
An Update on Lung NET Guidelines
October 07, 2018
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 07, 2018
Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs
October 06, 2018
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 06, 2018
Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options
October 06, 2018
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 06, 2018
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 05, 2018
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 05, 2018
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 05, 2018
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 05, 2018

Dr Thorvardur Halfdanarson Discusses Lack of Risk Factors, Biomarkers in NETs

There is a lot of disagreement, even within the neuroendocrine tumor (NET) circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.


There is a lot of disagreement, even within the neuroendocrine tumor (NET) circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.

Transcript

Are there any identified risk factors for developing neuroendocrine tumors?

Interesting question. So, we have studied that in pancreatic neuroendocrine tumors. We used a large dataset at the Mayo Clinic to look at that. We were not able to find anything that predicted NETs. For small bowel NETs, we know from large population studies in Sweden there may be a low famial risk. So, I would say all patients who have a first degree relative—a parent, or a child, or a sibling—with NETs should seek out one of these medical centers that are actually studying familial NETs, including the NIH [National Institutes of Health] and the University of Iowa.

As for other risk factors, we don’t know. They are becoming more common, partly because we’re better at diagnosing them, but also I think because they are becoming more common. We have essentially failed to identify risk factors.

Are there any identified biomarkers that guide treatment protocol?

It’s a hot topic. I would say for most NET patients, biomarkers add little. There is a lot of disagreement, even within the NET circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, and there are some that may have diagnostic value. The most commonly used one is chromogranin. It has such severe limitations for most parts that we can’t rely on it for diagnosis and we can’t really rely on it for treatment decisions.

There are other markers, including the marker called pancreostatin, which was discussed at a couple of posters here, that may have some better, more reliable characteristics than chromogranin A. And then there are some novel genomic markers that have been studied and look promising. But, essentially, larger studies are needed. What we need to know is really, we need to do studies that confirm or refute that these markers actually change treatment decisions and eventually change outcomes. If the marker is not going to change the outcomes, I don’t think we should do it.  

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!